“The S250i system represents the next generation of intensity modulated
proton therapy (IMPT) delivered in the most compact proton therapy
platform,” said Joseph Jachinowski, CEO of Mevion Medical Systems. “We
are proud that the MEVION S250i system now has received both FDA
clearance and CE mark. This is a very important milestone in our efforts
to make precision proton therapy available to more patients in the fight
against cancer.”

Pencil beam scanning systems shape the delivered radiation dose by
“painting” tumors spot-by-spot and layer-by-layer with sub-atomic
particles. Prior to HYPERSCAN PBS, scanning proton systems struggled
with delivery speed. Long delivery times can undermine the high
precision of the treatment due to the target tumor shifting under normal
organ motion such as breathing.

HYPERSCAN PBS uses a compact beam delivery path reducing delivery times
to less than 5 seconds for some fields. This “hyper-fast” treatment
delivery reduces treatment errors due to the sensitivity to motion that
current PBS technologies face when treating tumors affected by organ
motion.

In addition, HYPERSCAN PBS utilizes, the Adaptive Aperture™ proton
multi-leaf collimator (pMLC). This technology uses a robotically
controlled collimation system, capable of trimming the edges of the beam
at every layer of delivery. This capability delivers up to a three times
sharper drop off in radiation at the delivery field edge. This improves
sparing of healthy tissue and limits unnecessary radiation to sensitive
locations.

World’s First HYPERSCAN PBS InstallationMedStar
Georgetown University Hospital
in Washington, D.C. will be the first
hospital in the world to offer this latest generation of HYPERSCAN PBS
once final onsite testing is completed this month.

“We are excited to be not only the first and only proton therapy system
in the Washington, D.C. area, but also the first in the world to offer
these advanced proton therapy treatment capabilities to our patients and
community. Currently, patients who seek proton therapy need to leave the
metropolitan D.C. area, which can be a significant burden on families,”
said Brian T. Collins, MD, clinical director of MedStar Georgetown
Proton Therapy Center. “We will now be delivering advanced proton
therapy, fully integrated into our broad set of comprehensive cancer
care offerings. This is critical to the patients we serve.”

Built on Leading Compact Proton Therapy
Technology
The MEVION S250i system is based on Mevion’s
high efficiency, low financial risk S250™ Series platform. The core
technology of the S250 Series is the world’s only gantry mounted
superconducting synchrocyclotron. This compact, fully integrated
platform has years of successful clinical experience and proven
financial viability.

While proton therapy has clear dosimetric advantages, the costs of early
systems has been a significant barrier to adoption. The MEVION S250i
reduces this barrier through lower capital costs, reduced operating
costs, and increased treatment throughput. Mevion customers have
achieved the fastest per-room patient ramp-up in the history of proton
therapy. Demonstrating that compact proton therapy is a viable option
for any size cancer center is core to Mevion’s mission of making proton
therapy accessible to as many patients as possible.

About Mevion Medical Systems®
Mevion Medical Systems, Inc.
is a leading provider of proton therapy systems for use in radiation
treatment for cancer patients. Mevion is based in Littleton,
Massachusetts, with a presence in the Europe, Japan and China. For more
information, please visit www.mevion.com
.